The epidemiological effect and cost-effectiveness of expanded age eligibility for recombinant zoster vaccination in England. - Ku, C-C; Rosello, A; Walker, J; Pouwels, KB; Baguelin, M; Davies, NG; Jit, M (Vaccine, 2026)